Developer docs
API playgroundTry for free, no card

Search company profiles

jCyte

Full company profile

uuid0002bl1

Namestring
jCyte
Legal namestring
jCyte, Inc.
Websiteurl
jcyte.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

jCyte is a clinical-stage biotechnology company developing jCell (famzeretcel), a first-in-class allogeneic retinal progenitor cell (RPC) therapy for retinitis pigmentosa (RP) and other degenerative retinal disorders. Co-founded by Dr. Henry Klassen and Dr. Jing Yang and headquartered in Newport Beach, California, jCyte's lead candidate is administered as a single intravitreal injection designed to release neurotrophic factors that protect and restore surviving photoreceptors. Unlike gene therapy approaches that require patient-specific genetic matching, jCell is off-the-shelf and genotype-agnostic, allowing treatment across all genetic subtypes of RP—an addressable population of approximately 2 million patients worldwide (~100,000 in the U.S.) for whom there are no FDA-approved disease-modifying therapies.

The company's core technology is supported by a proprietary manufacturing process developed jointly with Center for Breakthrough Medicines (CBM) for Phase 3 trial supply and commercial-scale GMP production. jCell has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation from both the FDA and EMA. jCyte is currently advancing the JC02-88 Phase 2 trial (first patients dosed August 2025) evaluating a higher 8.8 million-cell dose in up to 60 RP patients, building toward a planned Phase 2/3 pivotal study following the FDA's January 2024 pre-Phase 3 Type B meeting. The company also maintains preclinical programs in diabetic retinopathy and optic nerve diseases, demonstrating pipeline expansion beyond the RP indication.

jCyte operates a dual commercial model: it retains U.S. commercialization rights and plans a direct launch through a specialty ophthalmology sales force, while Santen Pharmaceutical holds ex-U.S. rights (Europe and Asia) under a May 2020 licensing agreement valued at up to $252 million ($50M upfront cash, $12M convertible note, up to $190M in milestones, plus tiered double-digit royalties on net sales). The company has been funded primarily through non-dilutive California Institute for Regenerative Medicine (CIRM) grants totaling over $30 million and remains pre-revenue, with future revenue contingent on FDA BLA approval and subsequent commercialization in the U.S. and partner territories.

Short descriptiontext

jCyte is a clinical-stage biotechnology company developing jCell, a first-in-class allogeneic retinal progenitor cell therapy as an investigational treatment for retinitis pigmentosa and other degenerative retinal disorders currently in Phase 2 clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNewport Beach, United States
HQ citystring
Newport Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal cell therapy, regenerative medicine, ophthalmic biologics, clinical-stage biotechnology, cell-based therapeutics
Industry2 codes
PRIMARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Cell Therapy / Retinal Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Ex-U.S. Licensing Royalties (Santen)
TypeLicensing Royalties
Description

jCyte receives tiered, double-digit royalty payments on net commercial sales of jCell therapy in Europe and Asia under the 2020 licensing agreement with Santen Pharmaceutical. Royalties are payable upon commercialization in Santen's licensed regions.

jcyte.com
2Ex-U.S. Milestone Payments (Santen)
TypeLicensing Royalties
Description

jCyte is entitled to receive up to $190 million in clinical and sales milestone payments contingent on regulatory approval and initial commercial sales of jCell in Europe and Asia under the 2020 licensing agreement.

jcyte.com
3U.S. Product Sales (Post-Approval)
TypeOne Time License
Description

Upon BLA approval and commercialization of jCell in the United States, jCyte intends to generate revenue through direct product sales of jCell to hospitals, ambulatory surgical centers, and ophthalmology clinics. U.S. commercialization will be managed by the company's own commercial infrastructure.

jcyte.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

jCyte is a clinical-stage biotechnology company developing jCell (famzeretcel), a first-in-class allogeneic human retinal progenitor cell (hRPC) therapy administered as a single minimally invasive intravitreal injection for the treatment of retinitis pigmentosa (RP). The therapy works through sustained release of neurotrophic factors that reduce photoreceptor cell death and promote function of surviving cone and rod photoreceptors, and is genotype-agnostic across all RP genetic subtypes. The company is currently advancing the JC02-88 Phase 2 trial and plans to pursue BLA approval for direct U.S. commercialization while earning royalties from its Santen Pharmaceutical ex-U.S. licensing partnership.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2b: +16.27 letter improvement in BCVA vs. +1.85 for sham at 12 months (p=0.003) in target population receiving 6M cell dose
+3 more records
Product overview1 text field

jCyte is a clinical-stage biotech company developing jCell (famzeretcel), a first-in-class allogeneic cell therapy for retinitis pigmentosa and other degenerative retinal disorders. The lead product jCell is administered as a minimally invasive intravitreal injection and works by releasing neurotrophic factors to protect and restore photoreceptor function. The company is advancing JC02-88, a Phase 2 clinical trial, while also pursuing preclinical programs in diabetic retinopathy and optic nerve diseases. jCell has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from both FDA and EMA, positioning it for an expedited regulatory pathway.

Product and service4 records
1jCell (famzeretcel)
CategoryOphthalmic cell therapy — core investigational product
Description

First-in-class allogeneic human retinal progenitor cell (hRPC) therapy administered as a single, minimally invasive intravitreal injection for the treatment of retinitis pigmentosa (RP). The therapy works through sustained release of neurotrophic factors that reduce photoreceptor cell death and promote function of surviving cone and rod photoreceptors, and is genotype-agnostic across all RP genetic subtypes.

2JC02-88 Clinical Trial (8.8M cell dose pivotal trial)
CategoryClinical trial program
Description

Phase 2 clinical trial evaluating the safety and efficacy of a single 8.8 million cell intravitreal injection of jCell in approximately 60 RP patients aged 18–60 with any genetic subtype, BCVA 20/80–20/800, and central visual field diameter ≥8°, conducted at approximately 15 U.S. clinical trial sites with the UC Irvine Gavin Herbert Eye Institute as the central testing facility.

3Diabetic Retinopathy Program
CategoryPreclinical pipeline program
Description

Preclinical pipeline program investigating intravitreal human retinal progenitor cell transplantation for diabetic retinopathy, with cross-species efficacy (improved ERG b-wave, oscillatory potentials, optomotor response, contrast sensitivity; reduced VEGF expression and albumin extravasation) demonstrated in a rat model using human RPCs.

4Optic Nerve Disease Program
CategoryPreclinical pipeline program
Description

Research program exploring use of jCyte's allogeneic retinal progenitor cell platform for glaucoma and other optic nerve diseases.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCore / FlagshipTypeTechnology or IntegrationAnnounced on2022-09-20
Description

jCyte entered into a multi-year manufacturing agreement with Center for Breakthrough Medicines (CBM), a purpose-built cell and gene therapy CDMO based in Philadelphia's Cellicon Valley. CBM serves as the primary manufacturer of jCell for Phase 3 clinical trial supplies and commercial drug product following BLA approval. CBM also provides all BLA-enabling CMC work to support regulatory approval and commercialization. CBM offers fully dedicated manufacturing suites and analytical testing services tailored to jCyte's proprietary manufacturing process.

2Santen Pharmaceutical Co., Ltd.
Strategic tierCore / FlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-05-08
Description

jCyte entered into an ex-U.S. licensing and commercialization agreement with Santen Pharmaceutical for jCell therapy. Under the terms, jCyte received $50M upfront cash, $12M in a convertible note offering, and up to $190M in clinical and sales milestones based on regulatory approval and initial sales in Europe and Asia. jCyte is also entitled to tiered, double-digit royalty payments on net commercial sales. Santen gains exclusive rights to develop and commercialize jCell in all regions outside the U.S. The agreement leverages Santen's extensive global ophthalmology sales network, capabilities, and infrastructure covering over 60 countries.

jcyte.com
3Gavin Herbert Eye Institute, UC Irvine
Strategic tierCore / FlagshipTypeStrategic or Co-development Partner
Description

The Gavin Herbert Eye Institute at UC Irvine is a key strategic partner, serving as the primary treatment and manufacturing site for JC02-88 trial patients and providing GMP manufacturing capabilities through the UCI GMP Facility. The institute is led by Dr. Baruch Kuppermann (SAB member and department chair) and Dr. Henry Klassen (co-founder of jCyte). jCyte originated as a UCI startup company. The institute provides the central testing facility and primary clinical infrastructure for jCyte's pivotal trials.

jcyte.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Lexitas is a specialized clinical research organization with over 14 years dedicated exclusively to ophthalmology. Lexitas is a key partner supporting the JC02-88 clinical trial, providing clinical research services across the trial's network of approximately 15 U.S. clinical sites.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Foundation Fighting Blindness is a patient advocacy organization that has featured jCyte's clinical trial results and future plans in its communications to the RP patient community. The organization publishes podcasts (Eye on the Cure), research updates, and clinical trial announcements to help connect patients with experimental treatments under development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company developing treatments for inherited retinal diseases including retinitis pigmentosa and other ocular conditions. Directly comparable to jCyte in targeting RP and ophthalmology, though using AAV gene therapy rather than cell therapy.

TypeDirect peer
Description

Clinical-stage genetic medicines company with multiple ophthalmology programs including treatments for inherited retinal diseases like RP and choroideremia. Comparable as a late-stage ophthalmology therapeutic developer with similar patient population and regulatory pathway.

TypeDirect peer
Description

Clinical-stage biopharma developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Comparable as a developer of ophthalmology-targeted genetic/cell-based therapies for rare inherited blindness conditions.

TypeDirect peer
Description

Late-stage clinical biotech developing RNA editing therapies for inherited retinal diseases including retinitis pigmentosa (e.g., ultevursen for USH2A-related RP). Directly comparable as an RP-focused therapeutic developer using a different modality.

TypeBroad incumbent
Description

Clinical-stage gene therapy company with a leading AAV delivery platform used in multiple ophthalmology programs, including partnerships for retinal diseases. Comparable as a broader ocular gene therapy platform developer with deeper resources than jCyte.

TypeBroad incumbent
Description

Fully integrated gene therapy company (acquired by Roche) that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutation). Comparable as the established leader in retinal gene therapy and a benchmark for RP therapeutic commercialization.

TypeEmerging player
Description

Clinical-stage genetic medicines company developing AAV-based gene therapies for ocular and CNS diseases, including retinitis pigmentosa. Comparable as a smaller, emerging retinal gene therapy developer pursuing similar indications with a different modality.

TypeEmerging player
Description

Clinical-stage CRISPR genome editing company with an ophthalmology program targeting inherited retinal diseases including Leber congenital amaurosis. Comparable as an emerging ocular therapeutic developer using gene editing/cell therapy approaches for rare blindness conditions.

TypeEmerging player
Description

Clinical-stage biotech developing regenerative cell and small molecule therapies for degenerative eye diseases including retinitis pigmentosa and glaucoma. Closely comparable to jCyte as a cell-based therapy developer for retinal degenerative disease.

TypeBroad incumbent
Description

Large biopharma that acquired Nightstar Therapeutics in 2019 to enter the retinal gene therapy space (including RP programs). Comparable as a major player in the inherited retinal disease therapeutic space through prior M&A.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

jCyte

Ophthalmic Cell Therapy / Retinal Disease Therapeuticsjcyte.com

jCyte is a clinical-stage biotechnology company developing jCell, a first-in-class allogeneic retinal progenitor cell therapy as an investigational treatment for retinitis pigmentosa and other degenerative retinal disorders currently in Phase 2 clinical trials.

What jCyte does

jCyte is a clinical-stage biotechnology company developing jCell (famzeretcel), a first-in-class allogeneic retinal progenitor cell (RPC) therapy for retinitis pigmentosa (RP) and other degenerative retinal disorders. Co-founded by Dr. Henry Klassen and Dr. Jing Yang and headquartered in Newport Beach, California, jCyte's lead candidate is administered as a single intravitreal injection designed to release neurotrophic factors that protect and restore surviving photoreceptors. Unlike gene therapy approaches that require patient-specific genetic matching, jCell is off-the-shelf and genotype-agnostic, allowing treatment across all genetic subtypes of RP—an addressable population of approximately 2 million patients worldwide (~100,000 in the U.S.) for whom there are no FDA-approved disease-modifying therapies.

The company's core technology is supported by a proprietary manufacturing process developed jointly with Center for Breakthrough Medicines (CBM) for Phase 3 trial supply and commercial-scale GMP production. jCell has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation from both the FDA and EMA. jCyte is currently advancing the JC02-88 Phase 2 trial (first patients dosed August 2025) evaluating a higher 8.8 million-cell dose in up to 60 RP patients, building toward a planned Phase 2/3 pivotal study following the FDA's January 2024 pre-Phase 3 Type B meeting. The company also maintains preclinical programs in diabetic retinopathy and optic nerve diseases, demonstrating pipeline expansion beyond the RP indication.

jCyte operates a dual commercial model: it retains U.S. commercialization rights and plans a direct launch through a specialty ophthalmology sales force, while Santen Pharmaceutical holds ex-U.S. rights (Europe and Asia) under a May 2020 licensing agreement valued at up to $252 million ($50M upfront cash, $12M convertible note, up to $190M in milestones, plus tiered double-digit royalties on net sales). The company has been funded primarily through non-dilutive California Institute for Regenerative Medicine (CIRM) grants totaling over $30 million and remains pre-revenue, with future revenue contingent on FDA BLA approval and subsequent commercialization in the U.S. and partner territories.

jCyte firmographics

Firmographics
Name
jCyte
Legal name
jCyte, Inc.
Website
https://jcyte.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
jCyte is a clinical-stage biotechnology company developing jCell, a first-in-class allogeneic retinal progenitor cell therapy as an investigational treatment for retinitis pigmentosa and other degenerative retinal disorders currently in Phase 2 clinical trials.
Ownership category
akta.pro rank

jCyte industry classification

Industry
Product category
Ophthalmic Cell Therapy / Retinal Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Retinal cell therapy
  • Regenerative medicine
  • Ophthalmic biologics
  • Clinical-stage biotechnology
  • Cell-based therapeutics

Where jCyte is headquartered

Location

Headquarters

HQ city
Newport Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

jCyte business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Ex-U.S. Licensing Royalties (Santen): jCyte receives tiered, double-digit royalty payments on net commercial sales of jCell therapy in Europe and Asia under the 2020 licensing agreement with Santen Pharmaceutical. Royalties are payable upon commercialization in Santen's licensed regions.
  2. Ex-U.S. Milestone Payments (Santen): jCyte is entitled to receive up to $190 million in clinical and sales milestone payments contingent on regulatory approval and initial commercial sales of jCell in Europe and Asia under the 2020 licensing agreement.
  3. U.S. Product Sales (Post-Approval): Upon BLA approval and commercialization of jCell in the United States, jCyte intends to generate revenue through direct product sales of jCell to hospitals, ambulatory surgical centers, and ophthalmology clinics. U.S. commercialization will be managed by the company's own commercial infrastructure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

jCyte product offering

Product offering

Core offering

jCyte is a clinical-stage biotechnology company developing jCell (famzeretcel), a first-in-class allogeneic human retinal progenitor cell (hRPC) therapy administered as a single minimally invasive intravitreal injection for the treatment of retinitis pigmentosa (RP). The therapy works through sustained release of neurotrophic factors that reduce photoreceptor cell death and promote function of surviving cone and rod photoreceptors, and is genotype-agnostic across all RP genetic subtypes. The company is currently advancing the JC02-88 Phase 2 trial and plans to pursue BLA approval for direct U.S. commercialization while earning royalties from its Santen Pharmaceutical ex-U.S. licensing partnership.

Product overview

jCyte is a clinical-stage biotech company developing jCell (famzeretcel), a first-in-class allogeneic cell therapy for retinitis pigmentosa and other degenerative retinal disorders. The lead product jCell is administered as a minimally invasive intravitreal injection and works by releasing neurotrophic factors to protect and restore photoreceptor function. The company is advancing JC02-88, a Phase 2 clinical trial, while also pursuing preclinical programs in diabetic retinopathy and optic nerve diseases. jCell has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from both FDA and EMA, positioning it for an expedited regulatory pathway.

Differentiator

Problem solved

Functional benefit

Products and services

  • jCell (famzeretcel) First-in-class allogeneic human retinal progenitor cell (hRPC) therapy administered as a single, minimally invasive intravitreal injection for the treatment of retinitis pigmentosa (RP). The therapy works through sustained release of neurotrophic factors that reduce photoreceptor cell death and promote function of surviving cone and rod photoreceptors, and is genotype-agnostic across all RP genetic subtypes.
  • JC02-88 Clinical Trial (8.8M cell dose pivotal trial) Phase 2 clinical trial evaluating the safety and efficacy of a single 8.8 million cell intravitreal injection of jCell in approximately 60 RP patients aged 18–60 with any genetic subtype, BCVA 20/80–20/800, and central visual field diameter ≥8°, conducted at approximately 15 U.S. clinical trial sites with the UC Irvine Gavin Herbert Eye Institute as the central testing facility.
  • Diabetic Retinopathy Program Preclinical pipeline program investigating intravitreal human retinal progenitor cell transplantation for diabetic retinopathy, with cross-species efficacy (improved ERG b-wave, oscillatory potentials, optomotor response, contrast sensitivity; reduced VEGF expression and albumin extravasation) demonstrated in a rat model using human RPCs.
  • Optic Nerve Disease Program Research program exploring use of jCyte's allogeneic retinal progenitor cell platform for glaucoma and other optic nerve diseases.

Quantifiable outcome

  • Phase 2b: +16.27 letter improvement in BCVA vs. +1.85 for sham at 12 months (p=0.003) in target population receiving 6M cell dose
  • +3 more outcomes

Companies that use jCyte

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

jCyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

jCyte partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core / flagship and minor.

  • Center for Breakthrough Medicines (CBM)core / flagshipTechnology or Integration · 20 September 2022jCyte entered into a multi-year manufacturing agreement with Center for Breakthrough Medicines (CBM), a purpose-built cell and gene therapy CDMO based in Philadelphia's Cellicon Valley. CBM serves as the primary manufacturer of jCell for Phase 3 clinical trial supplies and commercial drug product following BLA approval. CBM also provides all BLA-enabling CMC work to support regulatory approval and commercialization. CBM offers fully dedicated manufacturing suites and analytical testing services tailored to jCyte's proprietary manufacturing process.
  • Santen Pharmaceutical Co., Ltd.core / flagshipOEM/ Whitelabel/ Licensing Partner · 8 May 2020jCyte entered into an ex-U.S. licensing and commercialization agreement with Santen Pharmaceutical for jCell therapy. Under the terms, jCyte received $50M upfront cash, $12M in a convertible note offering, and up to $190M in clinical and sales milestones based on regulatory approval and initial sales in Europe and Asia. jCyte is also entitled to tiered, double-digit royalty payments on net commercial sales. Santen gains exclusive rights to develop and commercialize jCell in all regions outside the U.S. The agreement leverages Santen's extensive global ophthalmology sales network, capabilities, and infrastructure covering over 60 countries.
  • Gavin Herbert Eye Institute, UC Irvinecore / flagshipStrategic or Co-development PartnerThe Gavin Herbert Eye Institute at UC Irvine is a key strategic partner, serving as the primary treatment and manufacturing site for JC02-88 trial patients and providing GMP manufacturing capabilities through the UCI GMP Facility. The institute is led by Dr. Baruch Kuppermann (SAB member and department chair) and Dr. Henry Klassen (co-founder of jCyte). jCyte originated as a UCI startup company. The institute provides the central testing facility and primary clinical infrastructure for jCyte's pivotal trials.
  • Lexitas (Clinical Research Organization)minorImplementation/ SI/ Consulting PartnerLexitas is a specialized clinical research organization with over 14 years dedicated exclusively to ophthalmology. Lexitas is a key partner supporting the JC02-88 clinical trial, providing clinical research services across the trial's network of approximately 15 U.S. clinical sites.
  • Foundation Fighting BlindnessminorGTM or Marketing PartnerFoundation Fighting Blindness is a patient advocacy organization that has featured jCyte's clinical trial results and future plans in its communications to the RP patient community. The organization publishes podcasts (Eye on the Cure), research updates, and clinical trial announcements to help connect patients with experimental treatments under development.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

jCyte competitors and assessment

Company assessment

Direct peers

  • MeiraGTx: Clinical-stage gene therapy company developing treatments for inherited retinal diseases including retinitis pigmentosa and other ocular conditions. Directly comparable to jCyte in targeting RP and ophthalmology, though using AAV gene therapy rather than cell therapy.
  • 4D Molecular Therapeutics: Clinical-stage genetic medicines company with multiple ophthalmology programs including treatments for inherited retinal diseases like RP and choroideremia. Comparable as a late-stage ophthalmology therapeutic developer with similar patient population and regulatory pathway.
  • GenSight Biologics: Clinical-stage biopharma developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Comparable as a developer of ophthalmology-targeted genetic/cell-based therapies for rare inherited blindness conditions.
  • ProQR Therapeutics: Late-stage clinical biotech developing RNA editing therapies for inherited retinal diseases including retinitis pigmentosa (e.g., ultevursen for USH2A-related RP). Directly comparable as an RP-focused therapeutic developer using a different modality.

Broad incumbents

  • REGENXBIO: Clinical-stage gene therapy company with a leading AAV delivery platform used in multiple ophthalmology programs, including partnerships for retinal diseases. Comparable as a broader ocular gene therapy platform developer with deeper resources than jCyte.
  • Spark Therapeutics (Roche): Fully integrated gene therapy company (acquired by Roche) that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutation). Comparable as the established leader in retinal gene therapy and a benchmark for RP therapeutic commercialization.
  • Biogen (Nightstar Therapeutics acquisition): Large biopharma that acquired Nightstar Therapeutics in 2019 to enter the retinal gene therapy space (including RP programs). Comparable as a major player in the inherited retinal disease therapeutic space through prior M&A.

Emerging players

  • Coave Therapeutics: Clinical-stage genetic medicines company developing AAV-based gene therapies for ocular and CNS diseases, including retinitis pigmentosa. Comparable as a smaller, emerging retinal gene therapy developer pursuing similar indications with a different modality.
  • Editas Medicine: Clinical-stage CRISPR genome editing company with an ophthalmology program targeting inherited retinal diseases including Leber congenital amaurosis. Comparable as an emerging ocular therapeutic developer using gene editing/cell therapy approaches for rare blindness conditions.
  • Endogena Therapeutics: Clinical-stage biotech developing regenerative cell and small molecule therapies for degenerative eye diseases including retinitis pigmentosa and glaucoma. Closely comparable to jCyte as a cell-based therapy developer for retinal degenerative disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

jCyte social profiles

Digital presence

jCyte compliance and trust

Trust signal

Compliance3 records

jCyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

jCyte leadership team

Management profile

Number of profiles

Profiles9 records

jCyte funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

jCyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about jCyte

What does jCyte do?

jCyte is a clinical-stage biotechnology company developing jCell (famzeretcel), a first-in-class allogeneic human retinal progenitor cell (hRPC) therapy administered as a single minimally invasive intravitreal injection for the treatment of retinitis pigmentosa (RP). The therapy works through sustained release of neurotrophic factors that reduce photoreceptor cell death and promote function of surviving cone and rod photoreceptors, and is genotype-agnostic across all RP genetic subtypes. The company is currently advancing the JC02-88 Phase 2 trial and plans to pursue BLA approval for direct U.S. commercialization while earning royalties from its Santen Pharmaceutical ex-U.S. licensing partnership.

Is jCyte a public or private company?

jCyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was jCyte founded?

jCyte was founded in 2015. It employs 1 to 10 people.

Where is jCyte based?

jCyte is headquartered in Newport Beach, United States, in the North America region.

How does jCyte make money?

Three revenue lines are on record. Ex-U.S. Licensing Royalties (Santen) is the primary driver. The others are ex-U.S. Milestone Payments (Santen) and U.S. Product Sales (Post-Approval).

Who are jCyte's main competitors?

Direct peers on record are MeiraGTx, 4D Molecular Therapeutics, GenSight Biologics and ProQR Therapeutics. Broad incumbents are REGENXBIO, Spark Therapeutics (Roche) and Biogen (Nightstar Therapeutics acquisition). Emerging players are Coave Therapeutics, Editas Medicine and Endogena Therapeutics.

Does jCyte have an API?

No public API is recorded for jCyte.

What industry is jCyte in?

jCyte's product category is Ophthalmic Cell Therapy / Retinal Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAK, Rare Ophthalmology Disorder Therapies, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCone Rod Dystrophy Market is Going to Booming Growth 2026-2033 | SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, JCyteThe global cone rod dystrophy market is projected to grow from USD 148.6 million in 2026 to USD 237.8 million by 2033, a CAGR of 7%. The report by Coherent Market Insights also profiles key players and segments the market by disease type, diagnosis, treatment, and end user.OcbjJCyte Launches Phase 2 Study to Treat Rare Eye DiseaseClinical-stage biotech company jCyte Inc. has enrolled the first patients in a Phase 2 study for its cell therapy treatment, jCell, targeting retinitis pigmentosa (RP). The trial, which involves approximately 60 participants and concludes in 2026, aims to evaluate the therapy's efficacy in improving vision and quality of life. This development follows a $252 million licensing agreement with Santen Pharmaceutical Co. for commercialization rights in Europe and Asia.ContractpharmaCenter for Breakthrough Medicines and jCyte Ink Manufacturing DealCenter for Breakthrough Medicines and jCyte signed a multi-year deal for CBM to manufacture jCyte's jCell cell therapy for retinitis pigmentosa. CBM will supply Phase 3 trial materials and commercial product after BLA approval, covering CMC work. The therapy targets nearly 2 million RP patients worldwide with no approved treatment.Business Wire BlogjCyte Announces Appointment of Dr. Stewart Craig as Chief Technology OfficerjCyte appointed Dr. Stewart Craig as Chief Technology Officer, making him strategic lead for drug product development and manufacturing. He brings over three decades of experience in cell and gene therapy, including prior roles at Erytech Pharma and Orchard Therapeutics. The appointment aims to support transitioning jCell's manufacturing from clinical to commercial stage.BioSpacejCyte Announces Expansion of Role for Chief Commercial Officer Samir ModyjCyte expanded Chief Commercial Officer Samir Mody's role to include global pricing, health economics, and reimbursement, supporting the North American launch of jCell. Mody brings over two decades of experience in market access and reimbursement from Medtronic and Johnson & Johnson. The expansion aims to optimize launch pricing and expedite jCell's commercial success.BioSpacejCyte Announces Appointment of R. Heath Coats as Vice President of CMC, Regulatory Compliance and Quality ControljCyte appointed R. Heath Coats as Vice President of CMC, Regulatory Compliance and Quality Control. He will lead manufacturing design, quality control, and regulatory filings for jCell, a regenerative cell therapy for retinitis pigmentosa. Coats brings over 30 years of experience, including time at the FDA and Parexel.